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Background: Acute pancreatitis is a major adverse event of endoscopic retrograde 
cholangiopancreatography (ERCP). Rectal administration of non-steroidal anti-
inflammatory drugs (NSAIDs) decreases the incidence of post-ERCP pancreatitis 
(PEP). However, the efficacy of low dose rectal NSAIDs for preventing PEP remains 
controversial.  
Methods: We performed a retrospective study of 301 patients with native papilla 
and a body weight of less than 50 kg who underwent ERCP between September 
2010 and October 2019. After July 2016, a 25 mg dose of rectal diclofenac was 
routinely administered within 15 minutes before ERCP (NSAIDs group, n = 72) 
and the control group (n=229) consisted in patients undergoing ERCP before this 
date without treatment. We compared the incidence of PEP between the two groups 
using propensity score-matching. 
Results: A total of 66 pairs of patients in each group were selected. The patients 
and procedural-related factors were similar in both groups. In total, 15 patients 
(11.4%) developed PEP: 12.1% (8/66) in the NSAIDs group and 10.6% (7/66) in the 
control group (Odds ratio (OR) 1.2; 95% confidence interval (CI) 0.4-3.5; p=0.78). 
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There was no significant difference in incidence of other adverse events related to 
ERCP between the two groups. 
Conclusions: Prophylactic administration of a 25mg dose of rectal diclofenac did not 
reduce the incidence of PEP in patients with a native papilla and a body weight of 
less than 50 kg in this study and a certain dose of rectal NSAIDs, such as a 100-mg 
dose, should be administered regardless of body weight to prevent PEP. 
 
 






















Acute pancreatitis is the most important adverse event (AE) of endoscopic retrograde 
cholangiopancreatography (ERCP), and post-ERCP pancreatitis (PEP) occurs in 1–
25% of patients [1-2]. Although PEP is usually mild or moderate, severe pancreatitis 
may develop in some cases, which requires further intervention and leads to death 
in 0.3–0.6% of the patients [3-6].  
Numerous pharmacological agents have been evaluated for the prevention of PEP. 
Several randomized trials have confirmed the efficacy of rectal non-steroidal anti-
inflammatory drugs (NSAIDs) in preventing PEP [7-10]. Routine rectal 
administration of diclofenac or indomethacin, immediately before an ERCP has been 
recommended to minimize the risk of PEP in the European Society of 
Gastrointestinal Endoscopy (ESGE) and Japanese Society of Hepato-Biliary-
Pancreatic Surgery (JHBPS) guidelines [11] [12]. 
However, the recommended dose, and that used in these trials, of rectal NSAIDs is 
100 mg, which is higher than the 25 mg dose that is usually administered in cases 
with a body weight less than 50 kg in Japan. But the efficacy of low dose rectal 
NSAIDs is unclear. The aim of the present study was to evaluate the efficacy of a 
25 mg dose of rectal diclofenac for the prevention of PEP compared to a control 
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Consecutive patients who underwent ERCP with a native papilla and body weight 
of less than 50 kg between September 2010 and October 2019 at Okayama University 
Hospital were included in this study. Among them, patients who met the following 
criteria were excluded: (1) presence of acute pancreatitis; (2) presence of chronic 
pancreatitis or pancreatic head tumor with occlusion of the main pancreatic duct (at 
low risk of PEP); and (3) contraindication to NSAIDs (in the NSAIDs group).  
In our institute, we prospectively administered a 25 mg dose of diclofenac 
suppository in patients whose body weight was less than 50 kg and a 50 mg dose of 
diclofenac suppository in patients whose body weight was greater than 50 kg within 
15 minutes before ERCP to prevent PEP after July 2016. We did not administer 
prophylactic diclofenac suppository prior to this date. Thus, we divided the eligible 
patients into two groups based on the administration of diclofenac (NSAIDs group 
and control group) and accordingly compared the incidence of PEP. This study was 





ERCP was performed with the patients in a prone or semi-prone position, under 
conscious sedation, and with CO2 insufflation. Pharyngeal anesthesia was induced 
by a topical anesthetic using a lidocaine spray, whereas conscious sedation was 
induced by an intravenous medication, mainly pethidine hydrochloride, and 
diazepam, just before the procedures. All ERCP procedures were carried out with a 
standard duodenoscope (TJF-260V or JF-260V; Olympus Medical System, Tokyo, 
Japan).  
The ERCP devices used were not limited to any specific types. We used a 
conventional cannulation technique that involved contrast injection at the first 
attempt, without the use of a guidewire. Injection of the contrast medium allowed 
visualization of the bile duct or pancreatic duct in order to confirm whether 
selective cannulation was achieved. In cases that were difficult to cannulate, we 
used pancreatic guidewire placement or pre-cut sphincterotomy to achieve selective 
cannulation. Pancreatic duct stenting was performed to prevent pancreatitis at the 
endoscopist’s discretion. We administered 20 mL of ulinastatin (150,000 U) 
solution, a protease inhibitor, by intravenous infusion immediately after the ERCP, 
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which is routinely used in our institution with the expectation that it will prevent 
PEP. All patients received intravenous 80 mL/h of Ringer’s lactate solution during 
the procedures generally and none of the patients received pre-procedural or post-
procedural aggressive hydration. After the procedures, the endoscopist recorded 
the results, and the patients fasted until the blood tests that were performed the 
following day confirmed the absence of pancreatitis or other AEs and resumed 
eating on the following day. For the purpose of observation, all of the patients in 
this study were hospitalized for at least 48 hours after the procedure. We assessed 
the patients the morning after the procedure and whenever the patients 
complained of pain. Abdominal pain was defined as new or worsening persistent 
pain in the epigastric region lasting more than 24 hours. Decisions regarding the 




Primary and secondary endpoints  
The primary endpoint was the occurrence of PEP. PEP was defined by the criteria 
set by Cotton et al. (13), as the development of abdominal pain and elevation of serum 
9 
 
amylase levels by more than 3 times the upper normal limit (hyperamylasemia) 
within 24 hours after an ERCP. The serum amylase level was measured before the 
ERCP, and when the patients complained of abdominal pain within 24 hours after 
the ERCP; otherwise, it was routinely measured 24 hours after the ERCP. The 
secondary endpoints included the development of moderate or severe PEP. The 
severity of PEP was graded according to the American Society for Gastrointestinal 
Endoscopy lexicon for endoscopic adverse events (14).  
 
The patient- and procedure-related factors were recorded at the end of procedures 
and compared between the two groups. Patient-related factors included the 
following: (1) age, (2) sex, (3) indication for ERCP, and (4) presence of previous 
pancreatitis. Procedure-related factors include the following: (1) main target duct, 
(2) pre-cut sphincterotomy, (3) endoscopic pancreatic sphincterotomy (EPS), (4) 
time for selective cannulation to the targeted duct initiated when cannulation was 
attempted, (5) presence of juxta papillary diverticulum, (6) endoscopic biliary 
sphincterotomy, (7) bile duct-intraductal ultrasonography, (8) endoscopic biliary 
drainage, (9) endoscopic papillary balloon dilation (EPBD) of the intact biliary 
sphincter , (10) injection of contrast agent into the pancreatic duct, (11) pancreatic 
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guidewire passage, (12) pancreatic duct stenting, and (13) total time for the ERCP 
procedure. The following factors were considered to be high risk for the occurrence 
of PEP: (1) clinical suspicion of sphincter of Oddi dysfunction (SOD), (2) female 
sex,(3) previous pancreatitis, (4) difficult cannulation (where successful selective 
cannulation took more than 10 minutes) or failed cannulation, (5) injection of 
contrast agent into the pancreatic duct, and (6) pancreatic guidewire passage (15).  
 
Statistical analysis 
Non-continuous variables were compared using the χ2 test, while continuous 
variables were compared using the Wilcoxon rank-sum test. A p-value < 0.05 was 
considered as statistically significant. 
We performed a propensity score matching analysis to control and reduce the 
confounding bias in each group and we compared the specific frequencies of PEP 
between the two groups with a similar background. A total of eight variables, namely, 
six definite risk factors for PEP (clinical suspicion of SOD, sex, history of pancreatitis, 
difficult cannulation, injection of the contrast agent into the pancreatic duct, and 
pancreatic guidewire passage) and two factors (main target duct and presence of 
endoscopic pancreatic stenting), which were imbalanced in baseline clinical 
characteristics and could possibly influence the frequency of PEP, were used to 
generate a propensity score using a multivariate logistic regression model. The 
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propensity score model was well calibrated and discriminated well between the 
NSAID and control groups (c-statistics = 0.69). The c-statistic was calculated by 
measuring the receiver-operating characteristic curve to assess the validity of the 
model. The patients were matched one-to-one using the nearest neighbor algorithm 
without replacement and a caliper width of 0.2 of the pooled standard deviation of 
the logit of the calculated propensity score. Absolute standardized differences (ASD) 
were estimated before and after matching to evaluate the balance of the histological 
findings of the enrolled patients in the NSAID and control groups. An ASD greater 
than 0.25 was considered to indicate a large imbalance. In the ancillary analysis, 
differences in PEP frequencies between the NSAID and control groups were tested 
in all cases by univariate logistic regression analysis. Moreover, odds ratios (ORs) 
and 95% confidence intervals (CIs) were estimated using the multivariate logistic 
regression model adjusting for eight variables that were used to generate a 
propensity score. All statistical analyses were performed using the JMP 12 software 





Between July 2010 and October 2019, 423 patients with native papilla and with a 
body weight less than 50 kg were scheduled to undergo ERCP and assessed for 
eligibility. Among them, 122 patients (28.8%) were excluded for fulfilling one of 
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previously outlined exclusion criteria (7 had presence of acute pancreatitis, 7 had 
presence of chronic pancreatitis, 95 had presence of pancreatic head tumor with 
occlusion of the main pancreatic duct, and 13 presented with contraindication for 
NSAIDs: renal failure (n=4), poor general condition due to severe comorbidity 
(n=4), NSAIDs allergy (n=3) and aspirin-induced asthma (n=2). Finally, the total 
number of patients included in the analysis was 301 (72 in the NSAID group vs. 
229 in the control group) (Figure 1).  
 
Demographic characteristics and endoscopic procedures 
The baseline characteristics of all patients (n = 301) are shown in Table 1. The 
NSAID group had higher proportions of female patients, patients with endoscopic 
biliary drainage, and patients with pancreatic duct stent placement, and lower 
prevalence of juxta papilla diverticulum than the control group. Moreover, 
examination in the NSAID group targeted the common bile duct more frequently 
and had a longer total procedure time. Among them, the higher frequency of 
pancreatic duct stenting in the NSAID group than in the control group was due to 
differences in the historical background. The 2 groups were similar with respect to 




After one-to-one propensity score-matching using eight factors, 66 pairs were 
selected from each group. The baseline characteristics of the 2 groups were 
comparable (Table 2). The number of patients at high risk of PEP was 62 (93.9%) 
and 62 (93.9%) in the NSAID and control groups, respectively (p = 1.00). 
 
Study outcomes 
The primary endpoint of PEP after the propensity score matching occurred in 15 
(11.4%) of the 132 patients, including 8 (12.1%) of the 66 patients in the NSAID 
group and 7 (10.6%) of the 66 patients in the control group (OR 1.2, 95%CI 0.4-3.4, 
p = 0.78). Severe or moderate PEP occurred in 4 patients (6.1%) in the NSAID 
group and 3 patients (4.6%) in the control group (OR 1.4, 95%CI 0.3-7.1, p = 0.70). 
All patients with PEP were discharged within 30 days after ERCP. There were no 
statistical differences in incidence and severity of PEP between the two groups. 
Low dose rectal NSAIDs did not significantly reduce the incidence of PEP and did 
not significantly improve the severity of PEP (Table 2).  
 
Result of the ancillary analysis 
PEP occurred in 12.3% (37/301) of the patients. Of these, 9 (12.5%) of the 72 patients 
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developed PEP in the NSAID group and 28 (12.2%) of the 229 patients in the control 
group ((OR 1.02; 95% CI 0.44-2.21; p = 0.95)). Similarly, low-dose rectal NSAIDs did 
not significantly reduce the incidence of PEP in multivariate analysis when adjusted 
for eight variables (OR 0.92; 95% CI 0.39-2.34; p = 0.92), which was the same as the 
result after propensity score matching. 
 
Other adverse events 
The median serum amylase level after the procedures was 132 (77–543) IU/L in the 
NSAIDs group and 133 (76–256) IU/L in the control group (p = 0.44), and 
hyperamylasemia was observed in 20 patients (30.3%) in the NSAIDs group and 11 
patients (16.7%) in the control group (p = 0.06). Moreover, there was no significant 
difference between the two groups in terms of bleeding, perforation, and biliary 
infection (Table 2). 
 
Discussion 
In some randomized controlled trials, rectal NSAIDs have shown significantly 
better prophylactic activity in PEP than that shown by placebo (7-10) and have 
been recommended to be administered in all patients without contraindications to 
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NSAIDs in the ESGE and JHBPS guidelines (11, 12). In this retrospective study, 
the rectal administration of very low dose (25 mg) NSAIDs did not prevent the 
occurrence of PEP. 
 
In nearly all previous studies performed in Western countries, the dose of rectal 
NSAIDs was 100 mg, which is different to that used in the present study (25 mg) 
(7-10). In Japan, it is recommended to administer a rectal dose of NSAIDs of 0.5–
1.0 mg per kg body weight; a dose of 100 mg is considered too high in Japan, where 
the majority of the people are under 100 kg, and a 25 mg dose is usually 
administered to patients who are less than 50 kg because the side effects of 
NSAIDs are dose dependent (16). Only a few studies have evaluated the effects of 
rectal NSAIDs for preventing of PEP at doses other than 100 mg, and the optimal 
dose of rectal NSAIDs is uncertain.  
 
Recently, a large scale multicenter randomized trial was conducted to compare the 
efficacy of high-dose regimen (200 mg) and standard-dose regimen (100 mg) of 
rectal NSAIDs on the frequency of PEP, and the high-dose regimen did not appear 
to offer any advantage over the standard-dose regimen (17). This result suggests 
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that the effect of NSAIDs in preventing PEP may not be dose dependent, and if low 
dose rectal NSAIDs can prevent PEP as well as the standard dose, it is likely to be 
safer than a standard dose. 
 
Two RCTs have evaluated the effect of low dose rectal NSAIDs (25 mg or 50 mg) on 
preventing PEP (18,19). Otsuka et al. reported that the occurrence of PEP among 
patients who received rectal diclofenac tended to be lower than in those who did 
not (2/51 [3.9%] vs. 10/53 [18.9%]; p=0.017). Conversely, Katoh et al. reported no 
difference among the two groups (8/147 [5.4%] in the diclofenac group and 5/150 
[3.3%] in the control group, p = 0.286). The former report had a small number of 
participants and the trial was performed at a center with a low volume of ERCP 
cases, while in the latter report, approximately half of the registered cases were 
low-risk patients, including those with non-native papilla and pancreatic head 
cancer; thus, the effect of low dose rectal NSAID administration remains 
controversial. In this study, the majority of the enrolled patients had a risk factor 
for PEP, as opposed to the previous two RCTs, and there was no significant 





Our study has some limitations. First, this study was retrospective in nature and 
was performed in a single center. Second, no conclusions could be drawn on the 
preventive effect of low-dose rectal NSAIDs on PEP owing to the small sample size. 
Therefore, a prospective, randomized, non-inferiority or equivalence trial involving 
a sufficient number of patients is required to confirm our results and further study 
evaluating the optimal dose of rectal NSAIDs for preventing PEP is needed. 
 
In conclusion, prophylactic administration of a 25mg dose of rectal diclofenac did 
not reduce the incidence of PEP in patients with a native papilla and a body weight 
of less than 50 kg in this study. We considered that very low doses of NSAIDs (25 
mg) cannot prevent PEP based on the results of this study, and a certain dose of 
rectal NSAIDs, such as a 100 mg dose, should be administered immediately before 
ERCP in patients without contraindications to NSAIDs regardless of body weight 
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Table 1. Patient and procedure-related factors of NSAIDs and control groups 
 All patients  Propensity-matched patients 
 NSAIDs group Control group 
P-value ASD 
 NSAIDs group Control group 
P-value ASD 
  (n=72) (n=229)   (n=66) (n=66) 
Patient-related factors          
     Body weight, Kg (range) 45(42-48) 45(41-47) 0.43 0.125   44 (42-48) 44 (41-47) 0.38  0.155  
     Age, year, median (range) 72(59-79) 71(62-78) 0.48 0.069   74 (62-80) 70 (62-77) 0.32  0.106  
     Sex, Female, n (%) 62(86.1%) 166(72.5%) 0.02 0.340   56 (84.9%) 56 (84.9%) 1.00  0.000  
     Indication, n (%)   0.40  0.106     - N.A* 
         Suspected for SOD 2 (2.8%) 3(1.3%)    0 (0%) 0 (0%)   
         Other disease 70 (97.2%) 226 (98.7%)    55 (100%) 55 (100%)   
              Malignant biliary disease 27 (37.5%) 66(28.8%)    25 (37.9%) 25 (37.9%)   
              Common bile duct stone 17 (23.6%) 42(18.3%)    15 (22.7%) 12 (18.2%)   
              Other benign biliary disease 12 (16.7%) 44(19.2%)    12 (18.2%) 15 (22.7%)   
              PDAC 5 (6.9%) 32(14.0%)    5 (7.6%) 4 (6.1%)   
              IPMN 7 (9.7%) 17(7.4%)    7 (10.6%) 1 (1.5%)   
              Other pancreatic disease 2 (2.8%) 25(10.9%)    2 (3.0%) 8 (12.1%)   
     History of recurrent pancreatitis, n (%) 1 (1.4%) 7 (3.1%) 0.44 0.113   1 (1.5%) 1 (1.5%) 1.00  0.000  
          
Procedures-related factors          
     Main target duct, n (%)   0.01  0.397     1.00  0.000  
         Common bile duct 61 (84.7%) 156(68.1%)    55 (83.3%) 55 (83.3%)   
         Pancreatic duct 11 (15.3%) 73(31.9%)    11 (16.7%) 11 (16.7%)   
     Success rate of selective cannulation, n (%) 71 (98.6%) 221(96.5%) 0.36 0.136   65 (98.5%) 63 (95.5%) 0.31  0.177  
     Precut sphincterotomy, n (%) 9 (12.5%) 24(10.5%) 0.63 0.063   9 (13.6%) 9 (13.6%) 1.00  0.000  
     Endoscopic pancreatic sphincterotomy, n (%) 3 (4.2%) 12(5.2%) 0.72 0.051   2 (3.0%) 5 (7.6%) 0.24 0.204  
     Time for selective cannulation, min (range) 7 (3-19) 5(2-14) 0.11 0.234   7 (3-19) 7 (3-17) 0.86  0.208  
     Difficult cannulation, n (%) 31 (43.1%) 84(36.7%) 0.33 0.130   27 (40.9%) 29 (43.9%) 0.72  0.051  
     Presence of juxta papilla diverticulum, n (%) 17 (23.6%) 29(12.7%) 0.02 0.286   13 (19.7%) 14 (21.2%) 0.83  0.037  
          
     Endoscopic biliary sphincterotomy, n (%) 39 (54.2%) 101(44.1%) 0.14 0.201   35 (53.0%) 28 (42.4%) 0.22  0.213  
     Common bile duct-intraductal ultrasonography, n (%) 18 (25.0%) 72 (31.4%) 0.30  0.143   15 (22.7%) 21 (31.8%) 0.24  0.205  
     Endoscopic biliary drainage, n (%) 36 (50.0%) 83(36.2%) 0.04 0.279   32 (48.5%) 26 (39.45) 0.29  0.183  
     EPBD of intact biliary sphincter, n (%) 1 (1.4%) 3(1.3%) 0.96 0.007   1 (1.5%) 1 (1.5%) 1.00  0.000  
          
     Pancreatic injection, n (%) 45 (62.5%) 148(64.6%) 0.74 0.044   39 (59.1%) 39 (59.1%) 1.00  0.000  
23 
 
     Pancreatic guidewire passage, n (%) 34 (47.2%) 92(40.2%) 0.29 0.142   28 (42.4%) 28 (42.4%) 1.00  0.000  
     Placement of pancreatic duct stent, n (%) 22 (30.6%) 30(13.1%) 0.0006 0.430   16 (24.2%) 16 (24.2%) 1.00  0.000  
     ERCP procedure time, min (range) 36 (21-59) 29(18-47) 0.04 0.331   36 (22-57) 34 (23-46) 0.46  0.208  
          
High risk state for PEP, n (%) 68 (94.4%) 214 (93.5%) 0.76 0.042   62 (93.9%) 62 (93.9%) 1.00  0.000  
     Patients with 1 risk factor for PEP 18 (25.0%) 60 (26.2%)    18 (29.0%) 18 (29.0%)   
     Patients with 2 or more risks factors for PEP 50 (69.4%) 154 (67.3%)       44 (66.7%) 44 (66.7%)     
 
ASD; Absolute standardized difference, NSAIDs: Non-steroidal anti-inflammatory 
drugs, SOD: Sphincter of Oddi dysfunction, PDAC: Pancreatic ductal 
adenocarcinoma, IPMN: Intraductal papillary mucinous neoplasm, EPBD: 
Endoscopic papillary balloon dilation, ERCP: Endoscopic retrograde 
cholangiopancreatography, PEP: Post-ERCP pancreatitis, N.A: not available 











Table 2. Incidence of post-ERCP pancreatitis and other adverse events 
 
 NSAIDs group Control group 
P-value OR 95%CI 
  n=66 n=66 
Post-ERCP pancreatitis in all patients, n (%) 8 (12.1%) 7 (10.6%) 0.78  1.2 0.4-3.5 
     Mild 4 (6.1%) 4 (6.1%) 1.00  1.0  0.2-4.4 
     Moderate or severe 4 (6.1%) 3 (4.6%) 0.70  1.4 0.3-7.1 
Other adverse events, n (%)      
     Hyperamylasemia 20 (30.3%) 11 (16.7%) 0.06  2.2 0.9-5.1 
     Bleeding 1 (1.5%) 1 (1.5%) 1.00  1.0  0.04-25.6 
     Perforation 0 (0%) 0 (0%) N.A   
     Biliary infection 1 (1.5%) 0 (0%) 0.23  N.A N.A 
 
ERCP: Endoscopic retrograde cholangiopancreatography, NSAIDs: Non-steroidal 














Figure 1: Flow chart of the patient selection process. 
 
ERCP: Endoscopic retrograde cholangiopancreatography, NSAIDs: Non-steroidal 
anti-inflammatory drugs 
 
